Tag:
Pearl Therapeutics
Latest Headlines
Latest Headlines
Pearl's porous particle platform nets $1.15B AstraZeneca buyout
In its $1.15 billion buyout of Pearl Therapeutics this week, AstraZeneca bolstered its late-stage drug development with a Phase III inhaled delivery platform to treat respiratory diseases.
UPDATED: AstraZeneca bags another PhIII therapy in $1.15B Pearl buyout
The Pearl Therapeutics buyout gives AstraZeneca's late-stage development director Briggs Morrison a Phase III respiratory therapy just days after the pharma giant was forced to throw in the towel on the rheumatoid arthritis drug fostamatinib.
Boehringer gets FDA panel's thumbs up on 'modest' new COPD treatment
Last week FDA staffers came up with a lukewarm review of the efficacy seen in Boehringer Ingelheim's prospective COPD drug olodaterol, but couldn't fault its safety profile. And that seemed to satisfy the panel of outside experts who met to review the drug today, giving it a pass with a lopsided 15-to-1 vote in favor of approval.
Pearl lands $65M round to fuel PhIII COPD showdown with Novartis, GSK
Pearl Therapeutics has grabbed a hefty $65 million venture round, enough to bankroll the launch of a key late-stage COPD drug program that--one way or another--will prove transformational for the biotech.
Forest Labs notches victory en route to FDA ruling on COPD drug
Eyeing the major market for a chronic lung condition, Forest Laboratories ( $FRX ) picked up the backing of an FDA panel for its experimental COPD drug known as aclidinium. It's a key endorsement...
PhRMA's COPD pipeline report spotlights blockbuster hopefuls
Anyone looking for a basic primer on experimental COPD drugs should check out PhRMA's latest compilation of new drugs in the pipeline. The big trade group found 54 COPD studies underway, which
Pearl's combo COPD treatment beats market rivals as it races to Ph3
Pearl Therapeutics put its combo LAMA/LABA treatment for COPD--PT003--up against two standard treatments for the lung disease and says it emerged with a commanding lead based on a key method for
Pearl lands $69M Series C for mid-stage COPD program
The four-year-old Pearl Therapeutics, which was founded by a pair of Nektar execs armed with some in-licensed particle technology that could be used to treat respiratory ailments, has rounded up $69
Pearl reports inhaled COPD drug results
Pearl Therapeutics has reported results from four studies supporting further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized
Pearl Therapeutics finds $15.5M in first VC round
Upstart Pearl Therapeutics, which is developing therapies for respiratory disorders, has raised $15.5 million in its first round. The Redwood City, CA-based biotech's round was co-led by New Leaf
